Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. 

For more information, visit www.cellistic.com. 


Biotechnology

Life Sciences

Therapeutics

Cellistic

Gustavo Mahler

Astrid Norenberg

Stefan Braam

Jonas Mortensen

Charles Jacques

Scientific and Engineering

Leadership Team

Teams at Cellistic

Scientific and Engineering

Leadership Team